Lipoprotein (a)
Lp(a) is an LDL-like particle with an added apolipoprotein(a) that is inherited and largely unaffected by diet or exercise. Elevated Lp(a) independently raises risk of heart attack, stroke, and calcific aortic stenosis. Because it is genetically set, a single lifetime measurement often suffices, and high values prompt more aggressive control of other cardiovascular risk factors.
Units: nmol/L or mg/dL (no fixed conversion: nmol/L counts particles and mg/dL weighs them; check which your lab reports). Check the units on your report before comparing to any range here.
Optimal range: who says what
Institutions, researchers and practitioners draw the line in different places. Each position is listed with who holds it and, where a document states it, a link. How we verify ranges.
- Institution or study<30 mg/dL (~75 nmol/L) desirable; >50 mg/dL (~125 nmol/L) elevated riskEAS consensus statement on lipoprotein(a) (2022)Largely genetic; measured once, managed via overall risk
- Institution or study<75 nmol/L (30 mg/dL) low risk; ≥125 nmol/L (50 mg/dL) high riskNational Lipid Association focused update (2024)Updates the 2019 NLA statement; 75-125 nmol/L (30-50 mg/dL) is intermediate risk
- Institution or study32-90 nmol/L minor risk; 90-200 moderate; 200-400 high; >400 very highHEART UK and Association for Laboratory Medicine joint statement (2025)HEART UK flags every result above 90 nmol/L as at least moderate risk and notes that converting nmol/L to mg/dL is assay specific and only a rough guide
- Institution or study≥50 mg/dL (≥125 nmol/L) is a risk-enhancing factor2018 AHA/ACC cholesterol guidelineMeasurement is relatively indicated with a family history of premature ASCVD
- Institution or studyNo safe threshold; risk rises about 11% per 50 nmol/LUK Biobank cohort (Patel et al. 2021, 460,506 adults)Risk rose linearly across the distribution; median Lp(a) was 19.6 nmol/L, with higher medians in South Asian and Black participants
- Named practitioner<50 nmol/LTracey O'Shea (Kresser Institute) · Understanding Lp(a): The Overlooked Marker of Cardiovascular Risk
- Lab reference intervalDesirable: <30 mg/dL, Borderline: 30-50 mg/dL, High: >50 mg/dLWhat a lab report flags against. A lab interval is not an optimal target.
Practitioner targets are individual positions, often tighter than guideline ranges. Each was checked against its article before publishing.
14 of 21 itemized panels
Lipid Panel / Cardiovascular Health
What is Lipoprotein (a)?
Lipoprotein (a), abbreviated as Lp(a), is a unique cholesterol particle consisting of an LDL-like particle with an additional protein called apolipoprotein(a) attached to it. Often called "the forgotten cholesterol," Lp(a) is a powerful independent risk factor for cardiovascular disease, stroke, and aortic valve stenosis. What makes Lp(a) particularly challenging is that your levels are 70-90% genetically determined and largely unresponsive to diet and lifestyle changes.
Lp(a) is highly atherogenic and prothrombotic, meaning it both promotes plaque formation and increases blood clotting tendency. The apolipoprotein(a) component has structural similarity to plasminogen, interfering with the body's clot-dissolving mechanisms. Lp(a) particles are smaller and more easily oxidized than regular LDL, making them particularly damaging to arterial walls. Approximately 20-30% of the population has elevated Lp(a) levels, often without knowing it.
Despite being discovered in 1963, Lp(a) has only recently gained widespread clinical attention as a critical cardiovascular risk factor. Elevated Lp(a) can explain premature heart disease in people with otherwise healthy lipid profiles and may account for much of the "residual risk" in statin-treated patients. Major cardiology societies now recommend at least one Lp(a) measurement in every adult's lifetime for risk stratification, as knowing your Lp(a) level can significantly impact cardiovascular prevention strategies.
Why Lipoprotein (a) Is Essential
- Independent genetic risk factor for cardiovascular disease
Interpretation bands (curated, PMID-backed)
Holder: OptimizeBiomarkers editorial synthesis of: Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis (Amiri et al., 2023); Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies (Genser et al., 2011); Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort (Wong et al., 2024). No single paper sets these cutoffs; for attributed targets see who says what.
Optimal<30 mg/dL or <75 nmol/L▼
Low cardiovascular and thrombotic risk.
Borderline30-50 mg/dL or 75-125 nmol/L▼
Moderately elevated; warrants attention to other CVD risk factors.
Very Low<10 mg/dL▼
Very low Lp(a) is not clinically concerning and may be protective.
High Risk>50 mg/dL or >125 nmol/L▼
- Significantly increased CVD risk
- Genetically determined, limited treatment options
- Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis.
- Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies.
- Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.
What raises or lowers Lipoprotein
Causes of high Lipoprotein
Primarily genetic (LPA gene variants); affects 20-30% of population. More common in African ancestry populations. Minor influences: postmenopausal status, hypothyroidism, nephrotic syndrome, kidney disease. NOT significantly affected by diet, exercise, or most medications.
Causes of low Lipoprotein
Genetic factors; low Lp(a) is associated with reduced cardiovascular risk and is considered protective
Symptoms when Lipoprotein is high or low
When high
No direct symptoms; elevated Lp(a) silently accelerates atherosclerosis, typically manifesting as premature coronary artery disease, stroke, or aortic valve stenosis decades later. Family history of early heart disease is often the only clue.
When low
Low Lp(a) (<10 mg/dL) is beneficial and protective against cardiovascular disease; no adverse effects
How to move Lipoprotein
Effect sizes (how much something moves the marker) appear only where the paper cited under the item states them. Talk to your clinician before starting or changing any medication or supplement.
Aspirin and Antiplatelet Therapy
Low-dose aspirin (81mg daily) may be particularly beneficial in patients with elevated Lp(a) due to its prothrombotic effects. Discuss with your physician, weighing bleeding risks against cardiovascular benefits. Evidence suggests aspirin may be more effective in high Lp(a) individuals.
Niacin (with caveats)
High-dose niacin (1-3g daily) lowers Lp(a) somewhat, but cardiovascular outcome benefits remain unproven and side effects are common. Generally not recommended as first-line therapy. Newer therapies are in development. Use only under physician supervision.
Emerging Therapies and Clinical Trials
Novel RNA-based therapies (antisense oligonucleotides, siRNA) lower Lp(a) substantially in trials and are being tested in cardiovascular outcome trials. Consider enrolling in clinical trials if you have very high Lp(a) (>200 nmol/L). Ask a lipid specialist about current availability.
When to retest
Lp(a) is genetically determined and stable throughout adulthood—one measurement is usually sufficient for lifetime risk assessment. Retest only if: initial measurement quality uncertain, starting specific Lp(a)-lowering therapy, or if levels were measured before age 20 (may increase until ~age 5).
Scientific Evidence
Lp(a) Drives Atherosclerosis, Not Venous Clots
A Mendelian randomization study of 41,231 people found genetically higher Lp(a) associated with coronary, carotid, and femoral artery stenosis and with myocardial infarction (hazard ratios 1.17-1.21 per doubling of Lp(a)), but not with venous thrombosis.
Lp(a), PCSK9 Inhibition, and Residual Risk
In 25,096 FOURIER patients, those in the top quartile of Lp(a) had higher coronary risk regardless of LDL cholesterol (hazard ratio 1.22 versus the bottom quartile). Evolocumab lowered Lp(a) by a median 26.9%; patients with above-median Lp(a) had a 23% reduction in coronary events versus 7% in those below the median.
Source: Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Lp(a) Testing in Clinical Practice
A National Lipid Association scientific statement describes Lp(a) as an independent risk factor for atherosclerotic disease, with observational and genetic evidence supporting a causal link to heart attack, stroke, and aortic valve stenosis. Elevated levels are estimated in 20% of the population. The statement reviews when to test in primary and secondary prevention.
Antisense Therapy to Lower Lp(a)
In a dose-ranging trial of 286 patients with cardiovascular disease and Lp(a) of at least 60 mg/dL, the antisense drug APO(a)-LRx lowered Lp(a) by 35% to 80% depending on dose, versus 6% with placebo. The trial measured Lp(a) levels, not cardiovascular events.
Source: Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
Which Providers Test Lipoprotein (a)?
Cheapest: Oura Health Panels at $99/year. Most comprehensive: Function Health, 160+ biomarkers for $365/year.
14 panels that include it, cheapest first
| Provider | Annual Cost | Total Biomarkers | $/Biomarker |
|---|---|---|---|
| $99 | 50 | $1.98 | |
| $190 | 100+ | $1.90 | |
| $297 | 100+ | $2.97 | |
 Superpower | $349 | 100+ | $3.49 |
| $349 | 75+ | $4.65 | |
 WHOOP Advanced Labs | $349 | 65 | $5.37 |
 Function Health | $365 | 160+ | $2.28 |
| $365 | 100+ | $3.65 | |
| $499 | 100+ | $4.99 | |
| $700 | 138 | $5.07 | |
| $895 | 100+ | $8.95 | |
| $996 | 59 | $16.88 | |
| $1188 | 70+ | $16.97 | |
| $1950 | 130+ | $15.00 |
$/Biomarker is annual cost divided by the panel's advertised biomarker count, not the price of this one test. We track 23 blood test providers (32 plans); 21 of those plans are itemized marker by marker. Compare all of them.
7 itemized panels do not include Lipoprotein (a)
Labcorp OnDemand · Life Extension Elite · Everlywell · InsideTracker · Marek Health Base · Marek Health Comprehensive · Vitality Blueprint Standard
11 providers not itemized in our matrix
We have not itemized these marker by marker (some sell tests one at a time), so this page cannot say whether they offer Lipoprotein (a). Check with them directly.
Life Extension Standard · Quest Health · Ultrahuman Blood Vision · Lifeforce · Hundred Health · Personalabs · Walk-In Lab · HealthLabs · WHOOP Specialized Panels · Marek Health Essential · Vitality Blueprint Upload
Experts discussing Lipoprotein (a)
Podcast episodes where clinicians and researchers cover this marker in depth. Curated by hand; an episode is listed only when the marker is a substantial topic, not a passing mention.
Frequently Asked Questions
What is the optimal range for Lipoprotein (a)?
Published positions differ: <30 mg/dL (~75 nmol/L) desirable; >50 mg/dL (~125 nmol/L) elevated risk (EAS consensus statement on lipoprotein(a) (2022)); <75 nmol/L (30 mg/dL) low risk; ≥125 nmol/L (50 mg/dL) high risk (National Lipid Association focused update (2024)); 32-90 nmol/L minor risk; 90-200 moderate; 200-400 high; >400 very high (HEART UK and Association for Laboratory Medicine joint statement (2025)); ≥50 mg/dL (≥125 nmol/L) is a risk-enhancing factor (2018 AHA/ACC cholesterol guideline); No safe threshold; risk rises about 11% per 50 nmol/L (UK Biobank cohort (Patel et al. 2021, 460,506 adults)). Named practitioners target: <50 nmol/L (Tracey O'Shea (Kresser Institute)). Lab reference interval: Desirable: <30 mg/dL, Borderline: 30-50 mg/dL, High: >50 mg/dL. That is what a lab report flags against, not an optimal target.
Which blood test providers include Lipoprotein (a)?
14 of the 21 blood testing panels we itemize marker by marker include Lipoprotein (a) in their panels. This biomarker is widely available across major providers.
Related: YouBoost rates lifestyle and supplement interventions by evidence; HRV Zone tracks recovery trends.
Medical Disclaimer
This information is for educational purposes only and is not medical advice. Always consult with a qualified healthcare provider about your specific health needs.
Last reviewed Sep 23, 2026 · First published Sep 30, 2025